Abstract
Virus-like particle (VLP) technology is an alternative platform for developing vaccines to combat seasonal and pandemic influenza. Influenza VLPs are non-infectious nanoparticles that can elicit effective vaccine immunogenicity in hosts. B-cell-activating factor (BAFF, or BLyS) and a proliferation-inducing ligand (APRIL) are members of the tumor necrosis factor (TNF) superfamily of cytokines. Both BAFF and APRIL are homotrimers that interact with homotrimeric receptors. Here, we report a method of the production of influenza VLPs by molecular incorporation with BAFF or APRIL homotrimers to interact with their receptors. We engineered the VLPs by direct fusion of BAFF or APRIL to the transmembrane anchored domain of the hemagglutinin (HA) gene. We also describe procedures for the production of BAFF-VLPs containing H5H7 and H1H5H7 for multi-subtype vaccine development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Haynes JR (2009) Influenza virus-like particle vaccines. Expert Rev Vaccines 8:435–445
Lopez-Macias C (2012) Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 8:411–414
Rossman JS, Lamb RA (2011) Influenza virus assembly and budding. Virology 411:229–236
Bright RA, Carter DM, Crevar CJ et al (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501
Quan FS, Huang C, Compans RW et al (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81:3514–3524
Ross TM, Mahmood K, Crevar CJ (2009) A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 4:e6032
Wei HJ, Chang W, Lin SC et al (2011) Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 29:7163–7172
Giles BM, Crevar CJ, Carter DM et al (2012) A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205:1562–1570
Giles BM, Ross TM (2011) A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043–3054
Wu CY, Yeh YC, Chan JT et al (2012) A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One 7:e42363
D'Aoust MA, Couture MM, Charland N et al (2010) The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 8:607–619
Landry N, Ward BJ, Trepanier S et al (2010) Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559
Lin SC, Liu WC, Lin YF et al (2013) Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnol J 8:1315–1322
Hossain MJ, Bourgeois M, Quan FS et al (2011) Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol 18:2010–2017
Perrone LA, Ahmad A, Veguilla V et al (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 83:5726–5734
Richert LE, Servid AE, Harmsen AL et al (2012) A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 30:3653–3665
Wang BZ, Xu R, Quan FS et al (2010) Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 5:e13972
Pearton M, Kang SM, Song JM et al (2010) Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS One 5:e12410
Quan FS, Kim YC, Vunnava A (2010) Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 84:7760–7769
Murphy K, Weaver C (2017) Janeway’s immunobiology, 9th edn. Garland Science, New York, London
Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18:263–275
Schuepbach-Mallepell S, Das D, Willen L et al (2015) Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties. J Biol Chem 290:16330–16342
Melchers M, Bontjer I, Tong T et al (2012) Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86:2488–2500
Gupta S, Clark ES, Termini JM et al (2015) DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol 89:4158–4169
Haley SL, Tzvetkov EP, Meuwissen S et al (2017) Targeting vaccine-induced extrafollicular pathway of B cell differentiation improves rabies postexposure prophylaxis. J Virol 91:e02435–e02416
Haley SL, Tzvetkov EP, Lytle AG et al (2017) APRIL:TACI axis is dispensable for the immune response to rabies vaccination. Antivir Res 144:130–137
Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30:991–1014
Hong JY, Chen TH, Chen YJ et al (2019) Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development. Antivir Res 164:12–22
Invitrogen (2015) Bac-to-Bac® Baculovirus Expression System an efficient site-specific transposition system to generate baculovirus for high-level expression of recombinant proteins. http://tools.thermofisher.com/content/sfs/manuals/bactobac_man.pdf. Accessed 13 Aug 2015
Liu WC, Liu YY, Chen TH et al (2016) Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design. Antivir Res 133:110–118
Acknowledgments
We thank the International Institute of Macromolecular Analysis and Nanomedicine Innovation, National Cheng Kung University, Taiwan, for TEM analysis. This work was supported by the Ministry of Science and Technology, Taiwan (MOST108-2321-B-007-001, MOST108-2321-B-002-006).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Chen, TH., Hong, JY., Liu, CC., Chen, CC., Jan, JT., Wu, SC. (2021). Production of Multi-Subtype Influenza Virus-Like Particles by Molecular Fusion with BAFF or APRIL for Vaccine Development. In: Bayry, J. (eds) The TNF Superfamily. Methods in Molecular Biology, vol 2248. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1130-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1130-2_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1129-6
Online ISBN: 978-1-0716-1130-2
eBook Packages: Springer Protocols